Artelo Biosciences Inc
Company Profile
Business description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Contact
505 Lomas Santa Fe
Suite 160
Solana BeachCA92075
USAT: +1 858 925-7049
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
CBA earnings: Business lending powers on, but costs and credit bear watching
stocks
Apple earnings review: Revenue beats estimates as memory crunch threatens margins
stocks
Nvidia: Cutting our fair value estimate by 19% given the firm’s CEO transition and turmoil
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,213.20 | 61.00 | -0.66% |
| CAC 40 | 8,361.36 | 28.49 | 0.34% |
| DAX 40 | 26,771.88 | 109.11 | 0.41% |
| Dow JONES (US) | 52,297.09 | 189.40 | -0.36% |
| FTSE 100 | 10,863.09 | 27.62 | 0.25% |
| HKSE | 23,786.48 | 222.07 | -0.92% |
| NASDAQ | 25,366.09 | 100.10 | -0.39% |
| Nikkei 225 | 61,334.76 | 515.40 | 0.85% |
| NZX 50 Index | 14,189.55 | 69.68 | -0.49% |
| S&P 500 | 7,592.40 | 26.98 | -0.35% |
| S&P/ASX 200 | 9,090.10 | 56.70 | -0.62% |
| SSE Composite Index | 3,663.71 | 7.88 | 0.22% |